Napo Pharmaceuticals, Inc. is a privately-held specialty pharmaceutical company based in South San Francisco, California. Founded in November 2001, Napo is developing a late-stage drug candidate, crofelemer, for gastrointestinal indications including chronic diarrhea in persons living with HIV/AIDS. Additionally, Napo has entered into a licensing agreement for the worldwide development and commercialization of crofelemer for Irritable Bowel Syndrome. Napo is also working with private/public partners to jointly develop crofelemer for pediatric indications in the developing world while maintaining commercial rights in the developed world.